144 related articles for article (PubMed ID: 15575020)
1. Post-transplant diabetes mellitus and renal function with tacrolimus: A decade of use, a decade of evidence. Foreword.
Vanrenterghem Y
Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi1-vi2. PubMed ID: 15575020
[No Abstract] [Full Text] [Related]
2. Improving long-term renal transplant outcomes with tacrolimus: speculation vs evidence.
First MR
Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi17-vi22. PubMed ID: 15575022
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant diabetes mellitus: the last 10 years with tacrolimus.
Bäckman LA
Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi13-vi16. PubMed ID: 15575021
[TBL] [Abstract][Full Text] [Related]
4. Conversion from tacrolimus to cyclosporine could improve control of posttransplant diabetes mellitus after renal transplantation.
Ramos-Cebrián M; Torregrosa JV; Gutiérrez-Dalmau A; Oppenheimer F; Campistol JM
Transplant Proc; 2007 Sep; 39(7):2251-3. PubMed ID: 17889154
[TBL] [Abstract][Full Text] [Related]
5. A late episode of post-transplant diabetes mellitus during active hepatitis C infection in a renal allograft recipient using tacrolimus.
van Duijnhoven EM; Christiaans MH; Boots JM; Goossens VJ; Undre NA; van Hooff JP
Am J Kidney Dis; 2002 Jul; 40(1):195-201. PubMed ID: 12087579
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus and angiotensin receptor blockers associated with changes in serum adiponectin level in new-onset diabetes after renal transplantation: single-center cross-sectional analysis.
Nishimura K; Kishikawa H; Kato T; Kobayashi Y; Fujii N; Takahara S; Ichikawa Y
Transpl Int; 2009 Jul; 22(7):694-701. PubMed ID: 19254242
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus based immunosuppression.
First MR
J Nephrol; 2004; 17 Suppl 8():S25-31. PubMed ID: 15599882
[TBL] [Abstract][Full Text] [Related]
8. Evaluating mechanisms of post-transplant diabetes mellitus.
van Hooff JP; Christiaans MH; van Duijnhoven EM
Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi8-vi12. PubMed ID: 15575024
[TBL] [Abstract][Full Text] [Related]
9. A decade of progress in kidney transplantation.
Vincenti F
Transplantation; 2004 May; 77(9 Suppl):S52-61. PubMed ID: 15201687
[TBL] [Abstract][Full Text] [Related]
10. New-onset diabetes after transplantation--should it be a factor in choosing an immunosuppressant regimen for kidney transplant recipients.
Chadban S
Nephrol Dial Transplant; 2008 Jun; 23(6):1816-8. PubMed ID: 18326882
[No Abstract] [Full Text] [Related]
11. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation.
Porrini E; Delgado P; Alvarez A; Cobo M; Pérez L; González-Posada JM; Hortal L; Gallego R; García JJ; Checa M; Morales A; Salido E; Hernández D; Torres A
Nephrol Dial Transplant; 2008 Apr; 23(4):1436-41. PubMed ID: 18029372
[TBL] [Abstract][Full Text] [Related]
12. Renal function: defining long-term success.
Pascual J; Marcén R; Ortuño J
Nephrol Dial Transplant; 2004 Dec; 19 Suppl 6():vi3-vi7. PubMed ID: 15575023
[TBL] [Abstract][Full Text] [Related]
13. Spectrum of surgical complications after simultaneous pancreas-kidney transplantation in a prospectively randomized study of two immunosuppressive protocols.
Steurer W; Malaise J; Mark W; Koenigsrainer A; Margreiter R;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii54-62. PubMed ID: 15814551
[TBL] [Abstract][Full Text] [Related]
14. Generic tacrolimus (Pan Graf) in renal transplantation: an experience of 155 recipients in India.
Guleria S; Kamboj M; Chatterjee A; Sharma M; Awasthy V; Dinda A; Mahajan S; Bhowmik D; Gupta S; Agarwal SK; Tiwari SC
Transplant Proc; 2008 Sep; 40(7):2237-9. PubMed ID: 18790202
[TBL] [Abstract][Full Text] [Related]
15. Risk factors and consequences of post-transplant diabetes mellitus.
Demirci MS; Toz H; Yilmaz F; Ertilav M; Asci G; Ozkahya M; Zeytinoglu A; Nart D; Ok E
Clin Transplant; 2010; 24(5):E170-7. PubMed ID: 20384711
[TBL] [Abstract][Full Text] [Related]
16. Evolution of tacrolimus blood levels and concentration-dose ratios in patients who develop new onset diabetes mellitus after kidney transplantation.
Rodrigo E; Piñera C; de Cos MA; Sánchez B; Ruiz JC; Fernández-Fresnedo G; Palomar R; González-Cotorruelo J; Gómez-Alamillo C; de Castro SS; de Francisco AL; Arias M
Transpl Int; 2005 Oct; 18(10):1152-7. PubMed ID: 16162102
[TBL] [Abstract][Full Text] [Related]
17. Safety analysis after tacrolimus immunosuppression in renal transplant recipients in Japan: 5-year results in >1500 patients.
Yoshimura N; Takahara S; Uchida K; Takahashi K; Toma H; Oshima S; Sonoda T;
Transplant Proc; 2005 May; 37(4):1764-6. PubMed ID: 15919458
[TBL] [Abstract][Full Text] [Related]
18. [Post-transplant diabetes mellitus associated with acute hepatitis C virus infection in a renal transplant recipient].
Gavela E; Crespo JF; Sancho A; Avila A; Núñez A; Molina P; Pallardó LM
Nefrologia; 2004; 24(1):75-8. PubMed ID: 15083962
[TBL] [Abstract][Full Text] [Related]
19. Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors?
Nashan B
Transplant Rev (Orlando); 2009 Jan; 23(1):47-52. PubMed ID: 19027616
[TBL] [Abstract][Full Text] [Related]
20. Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression.
Sharma A; Minz M; Singh S
Transplant Proc; 2008 Sep; 40(7):2414-5. PubMed ID: 18790252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
